Beta-blockers improve clinical outcomes in heart failure and reduced ejection fraction (HFrEF); but not in those with preserved EF. Global longitudinal strain (GLS) is a prognostic factor independent of left ventricular ejection fraction (LVEF). In a retrospective with 1969 patients with HF and LVEF of ≥40%, beta-blocker was associated with improved survival in those with low GLS (GLS \<14%), but not in those with GLS ≥14%. In this prospective, randomized clinical study, the investigators will assess the effect of slow-release carvedilol in patients with HFpEF and hypertension. The primary endpoint is the time-averaged proportional changes in NT-proBNP level and GLS change from baseline to month 6.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
63
patients randomized to carvedilol group will receive carvedilol-SR.
patients randomized to placebo group will receive placebo.
Samsung Medical Center
Seoul, Il-won, South Korea
Wonju Severance Christian Hospital
Wŏnju, WONJU, South Korea
NT-proBNP change
Time averaged NT-proBNP change from baseline to 6 months
Time frame: 6 months
GLS change
Change of GLS from baselin to 6 months
Time frame: 6 months
off-level NT-proBNP
Decrease in NT-proBNP \> 10% from baseline to 6 months
Time frame: 6 months
Mortality
All-cause mortality from baseline to 6 months
Time frame: 6 months
rehospitalization
rehospitalization from baseline to 6 months
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.